Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Correction

Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study

Samuel Frank* and Huntington Study Group/TETRA-HD Investigators

Author Affiliations

72 East Concord St., C329, Boston, MA 02118, USA

For all author emails, please log on.

BMC Neurology 2011, 11:18  doi:10.1186/1471-2377-11-18

Published: 4 February 2011

First paragraph (this article has no abstract)

After publication of this work [1], we became aware of a typographical error. The term dysphagia inadvertently replaced the term dysarthria in two instances. Dysarthria was statistically significantly worsened at week 80 compared to baseline, whereas there was only a statistical trend (p = 0.10) for dysphagia at week 80 compared to baseline. Dysphagia continues to be an issue in patients with Huntington Disease and was reported as an adverse event in this study. Therefore, clinicians who prescribe tetrabenazine should still monitor their patients for worsening swallowing, but the worsening was not statistically different in those who completed this trial. No further studies of tetrabenazine in Huntington Disease have been completed since the publication of this study.